Brokerages Set Definitive Healthcare Corp. (NASDAQ:DH) Target Price at $1.47

Definitive Healthcare Corp. (NASDAQ:DH) has been assigned an average recommendation of “Reduce” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $1.4714.

A number of equities research analysts recently issued reports on the company. BTIG Research reissued a “neutral” rating on shares of Definitive Healthcare in a research note on Friday, September 4th. Bank of America restated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a research note on Monday, June 29th. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Morgan Stanley lowered their target price on shares of Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Monday, August 31st.

Institutional Investors Weigh In On Definitive Healthcare

A number of large investors have recently modified their holdings of the business. Squarepoint Ops LLC lifted its stake in shares of Definitive Healthcare by 46.5% in the second quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock worth $292,000 after buying an additional 111,634 shares in the last quarter. Corient Private Wealth LP acquired a new stake in Definitive Healthcare in the 2nd quarter valued at about $378,000. Williams & Novak LLC increased its stake in shares of Definitive Healthcare by 155.8% in the 2nd quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock worth $65,000 after acquiring an additional 47,880 shares during the last quarter. Irenic Capital Management LP purchased a new position in shares of Definitive Healthcare during the 1st quarter worth $71,000. Finally, Flywheel Private Wealth LLC purchased a new position in shares of Definitive Healthcare during the 1st quarter worth $83,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Trading Down 6.2%

Shares of Definitive Healthcare stock opened at $0.90 on Tuesday. The company’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $0.90. The stock has a market capitalization of $96.08 million, a PE ratio of -0.56, a P/E/G ratio of 11.85 and a beta of 1.40. Definitive Healthcare has a 1-year low of $0.61 and a 1-year high of $4.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Monday, August 10th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The firm had revenue of $55.20 million during the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. As a group, equities analysts anticipate that Definitive Healthcare will post 0.06 earnings per share for the current year.

About Definitive Healthcare

Definitive Healthcare Corp. (NASDAQ: DH) provides commercial intelligence and data analytics solutions for the healthcare industry. Its platform is designed to help organizations identify and understand healthcare providers, institutions, markets and patient populations, supporting decisions related to sales, marketing, market access, strategy and business development.

The company’s products and services include healthcare provider and facility data, claims-based insights, organizational and affiliation information, analytics tools, workflow solutions and intelligence related to clinical trials and healthcare markets.